1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797386829451755520 |
|---|---|
| author | Matthew Zhou William Mallet Romas Kudirka Han K Kim Justin Monnier Chi-Ling Fu Jennifer E Melrose Hung Dao Paul D Ponath Katelynn A McEachin David T Omstead Cindy Kreder Stefan Chun Ying Yueh Lee Rachel Grgich Tracey J Lin Joshua A Walker Karla A Henning Shelley E Ackerman Diane Carrera Steven J Chapin Dowdy Jackson Changshou Gao Michael N Alonso |
| author_facet | Matthew Zhou William Mallet Romas Kudirka Han K Kim Justin Monnier Chi-Ling Fu Jennifer E Melrose Hung Dao Paul D Ponath Katelynn A McEachin David T Omstead Cindy Kreder Stefan Chun Ying Yueh Lee Rachel Grgich Tracey J Lin Joshua A Walker Karla A Henning Shelley E Ackerman Diane Carrera Steven J Chapin Dowdy Jackson Changshou Gao Michael N Alonso |
| author_sort | Matthew Zhou |
| collection | DOAJ |
| first_indexed | 2024-03-08T22:15:03Z |
| format | Article |
| id | doaj.art-30e7900b97ae4dd8a324a8032d05c871 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-08T22:15:03Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-30e7900b97ae4dd8a324a8032d05c8712023-12-19T02:10:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 210.1136/jitc-2023-SITC2023.1147-D1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profileMatthew Zhou0William Mallet1Romas Kudirka2Han K Kim3Justin Monnier4Chi-Ling Fu5Jennifer E Melrose6Hung Dao7Paul D Ponath8Katelynn A McEachin9David T Omstead10Cindy Kreder11Stefan Chun12Ying Yueh Lee13Rachel Grgich14Tracey J Lin15Joshua A Walker16Karla A Henning17Shelley E Ackerman18Diane Carrera19Steven J Chapin20Dowdy Jackson21Changshou Gao22Michael N Alonso231Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA1Bolt Biotherapeutics, Redwood City, CA, USA2Innovent Biologics USA, Rockville, MD, USA2Innovent Biologics USA, Rockville, MD, USA1Bolt Biotherapeutics, Redwood City, CA, USA |
| spellingShingle | Matthew Zhou William Mallet Romas Kudirka Han K Kim Justin Monnier Chi-Ling Fu Jennifer E Melrose Hung Dao Paul D Ponath Katelynn A McEachin David T Omstead Cindy Kreder Stefan Chun Ying Yueh Lee Rachel Grgich Tracey J Lin Joshua A Walker Karla A Henning Shelley E Ackerman Diane Carrera Steven J Chapin Dowdy Jackson Changshou Gao Michael N Alonso 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile Journal for ImmunoTherapy of Cancer |
| title | 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile |
| title_full | 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile |
| title_fullStr | 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile |
| title_full_unstemmed | 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile |
| title_short | 1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile |
| title_sort | 1147 d preclinical characterization of a novel claudin 18 2 targeting isac with robust potency and acceptable safety profile |
| work_keys_str_mv | AT matthewzhou 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT williammallet 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT romaskudirka 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT hankkim 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT justinmonnier 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT chilingfu 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT jenniferemelrose 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT hungdao 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT pauldponath 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT katelynnamceachin 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT davidtomstead 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT cindykreder 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT stefanchun 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT yingyuehlee 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT rachelgrgich 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT traceyjlin 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT joshuaawalker 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT karlaahenning 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT shelleyeackerman 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT dianecarrera 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT stevenjchapin 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT dowdyjackson 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT changshougao 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile AT michaelnalonso 1147dpreclinicalcharacterizationofanovelclaudin182targetingisacwithrobustpotencyandacceptablesafetyprofile |